- Celiac Disease
- About Us
- Pipeline & Trials
- News & Events
Celimmune has in-licensed AMG 714 for the treatment of diet non-responsive celiac disease and refractory celiac disease II (RCD II) from Amgen (NASDAQ:AMGN).
More details about Celimmune’s AMG 714 license transaction can be found at www.amgenbd.com.
We count on the support of a trusted network of collaborators, including: